More competition in the drug industry would prevent situations like the big price hike in Mylan's (MYL) EpiPens, according to TheStreet's Jim Cramer. He says pharmaceutical companies know they can raise drug prices when competition is scarce. On Thursday, Mylan's CEO discussed the EpiPen price increase on CNBC. Cramer said the honorable thing for CEO Heather Bresch to do would have been to announce a cut in EpiPen prices, which did not happen.
More from Video
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.